Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628198 · ClinicalTrials.gov registry record · NA
Impact of Renal SympAthetic DenerVation on Chronic HypErtension
A NA study, sponsored by Vivek Reddy.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT01628198 is a NA study that was terminated before completion, run by Vivek Reddy. The registered enrollment target is 38 participants.
The verdict
NCT01628198, a NA study, was terminated before completion, sponsored by Vivek Reddy.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Despite the development of many drug therapies designed to treat high blood pressure (hypertension), it remains a considerable and poorly managed health, social and economic burden. For various reasons, including the high health care costs of treatment, there are estimates that up to 65% of patients with high blood pressure have untreated and/or uncontrolled blood pressure (BP). Aside from its effect on kidney function, chronic high blood pressure increases the risk for stroke, and heart disease. It is also thought to be involved in the formation of irregular heartbeats. This link between high blood pressure and heart health has been well described, as has their combined effect on the aging and the obesity-battling Western world. A recently published study (Symplicity HTN-2 trial) established the benefit of a new treatment procedure, catheter-based renal sympathetic denervation (RSDN) for hypertension, as having enormous potential for the treatment of patients with high blood pressure. This multi-center trial will attempt to confirm and expand on these promising data. Patients who enroll in the trial will be followed for 4 years.
Interventions
- DEVICE Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01628198
The ClinicalTrials.gov registry entry for NCT01628198 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vivek Reddy, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter is the first listed.
NCT01628198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01628198 about?
NCT01628198 is a clinical study titled "Impact of Renal SympAthetic DenerVation on Chronic HypErtension". Despite the development of many drug therapies designed to treat high blood pressure (hypertension), it remains a considerable and poorly managed health, social and economic burden. For various reasons, including the high health care costs of treatment, there are estimates that up to 65% of patients...
What is the current status of trial NCT01628198?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2011-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01628198?
The interventions under investigation include: Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter (DEVICE).
Who is sponsoring clinical trial NCT01628198?
This trial is sponsored by Vivek Reddy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.